Indi Molecular, Inc.

California Institute of Technology

Regeneron Pharmaceuticals, Inc.

Bert Tsunyin Lai

Heather Dawn Agnew

Anders Eliasen

James R Heath

Arundhati Nag

Samir Das

Blake Farrow

Suresh Mark Pitram

David Bunck

Jingxin Liang

The present application provides stable heterobiligands made up of peptide-based IDO1 ligands and small molecule inhibitors of IDO1 and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing IDO1 heterobiligands, capture agents, and imaging agents.

Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)

The present application provides stable peptide-based IDO1 capture agents and methods of use as detection, imaging, diagnostic and therapeutic agents. The application further provides methods of manufacturing IDO1 imaging agents.

Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

Disclosed are compounds, compositions, systems, and methods useful for treating disease (such as cancer and tumors), or binding, detecting, and affecting compounds, compositions, cells, tissues, and organs, where the compounds, compositions, systems, and methods include or involve toxic compounds and where the toxic effect of the compounds, compositions, systems, and methods is reduced by providing a cleavage site to facilitate separation of the toxic component from other components of the compound, composition, or system. Preferably the system is a composition delivery system comprising or using a composition as disclosed herein. In some forms, the cleavage of the composition delivers a therapeutic agent and avoids organ damage by the composition.

Compositions, delivery systems, and methods useful in tumor therapy

The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.

Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1)

The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making

The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

Growing community of inventors

Culver City, CA, United States of America

Bert Tsunyin Lai